Literature DB >> 26816662

Association between Apolipoprotein C-III Gene Polymorphisms and Coronary Heart Disease: A Meta-analysis.

Jing-Zhan Zhang1, Xiang Xie1, Yi-Tong Ma1, Ying-Ying Zheng1, Yi-Ning Yang1, Xiao-Mei Li1, Zhen-Yan Fu1, Chuan-Fang Dai1, Ming-Ming Zhang1, Guo-Ting Yin1, Fen Liu1, Bang-Dang Chen1, Min-Tao Gai1.   

Abstract

Polymorphisms in the apolipoprotein C-III (APOC3) gene have been reported to be associated with coronary heart disease (CHD), but the data so far have been conflicting. To derive a more precise estimation of these associations, we performed a meta-analysis to investigate the three main polymorphisms (SstI, T-455C, C-482T) of APOC3 in all published studies. Databases including PubMed, Web of Science, Wanfang, SinoMed and CNKI were systematically searched. The association was assessed using odds ratios (ORs) with 95% confidence intervals (CIs). The statistical analysis was performed using Review Manager 5.3.3 and Stata 12.0. A total of 31 studies have been identified. The pooled odds ratio (OR) for the association between the APOC3 gene polymorphisms and CHD and its corresponding 95% confidence interval (95% CI) were evaluated by random or fixed effect models. A statistical association between APOC3 SstI polymorphism and CHD susceptibility was observed under an allelic contrast model (P= 0.003, OR = 1.14, 95% CI = 1.05-1.24), dominant genetic model (P= 0.01, OR = 1.14, 95% CI = 1.03-1.26), and recessive genetic model (P= 0.02, OR = 1.35, 95% CI = 1.06-1.71), respectively. A significant association between the APOC3 T-455C polymorphism and CHD was also detected under an allelic contrast (P < 0.0001, OR = 1.19, 95% CI = 1.10-1.29), dominant genetic model (P= 0.0003, OR = 1.24, 95% CI = 1.11-1.39) and recessive genetic model (P= 0.04, OR = 1.30, 95% CI = 1.01-1.67). No significant association between the APOC3 C-482T polymorphism and CHD was found under an allelic model (P= 0.94, OR = 1.00, 95% CI = 0.93-1.08), dominant genetic model (P= 0.20, OR = 1.07, 95% CI = 0.97-1.18) or recessive genetic model (P= 0.13, OR = 0.90, 95% CI = 0.79-1.03). This meta-analysis revealed that the APOC3 SstI and T-455C polymorphisms significantly increase CHD susceptibility. No significant association was observed between the APOC3 C-482T polymorphism and CHD susceptibility.

Entities:  

Keywords:  APOC3; Coronary heart disease; Meta-analysis; Polymorphism

Year:  2016        PMID: 26816662      PMCID: PMC4723232          DOI: 10.14336/AD.2015.0709

Source DB:  PubMed          Journal:  Aging Dis        ISSN: 2152-5250            Impact factor:   6.745


  33 in total

1.  DNA polymorphisms of apolipoprotein A-I/C-III and insulin genes in familial hypertriglyceridemia and coronary heart disease.

Authors:  K Aalto-Setälä; K Kontula; T Sane; M Nieminen; E Nikkilä
Journal:  Atherosclerosis       Date:  1987-07       Impact factor: 5.162

2.  Restriction fragment length polymorphisms of the apolipoprotein A-I, C-III, A-IV gene locus. Relationships with lipids, apolipoproteins, and premature coronary artery disease.

Authors:  J M Ordovas; F Civeira; J Genest; S Craig; A H Robbins; T Meade; M Pocovi; P M Frossard; U Masharani; P W Wilson
Journal:  Atherosclerosis       Date:  1991-03       Impact factor: 5.162

3.  A random-effects regression model for meta-analysis.

Authors:  C S Berkey; D C Hoaglin; F Mosteller; G A Colditz
Journal:  Stat Med       Date:  1995-02-28       Impact factor: 2.373

4.  Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia.

Authors:  W W Li; M M Dammerman; J D Smith; S Metzger; J L Breslow; T Leff
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

5.  Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice.

Authors:  Y Ito; N Azrolan; A O'Connell; A Walsh; J L Breslow
Journal:  Science       Date:  1990-08-17       Impact factor: 47.728

6.  A prospective study of the APOA1 XmnI and APOC3 SstI polymorphisms in the APOA1/C3/A4 gene cluster and risk of incident myocardial infarction in men.

Authors:  Simin Liu; Yiqing Song; Frank B Hu; Tianhua Niu; Jing Ma; Michael Gaziano; Meir J Stampfer
Journal:  Atherosclerosis       Date:  2004-11       Impact factor: 5.162

7.  Synergistic effects of the apolipoprotein E epsilon3/epsilon2/epsilon4, the cholesteryl ester transfer protein TaqIB, and the apolipoprotein C3 -482 C>T polymorphisms on their association with coronary artery disease.

Authors:  A Muendlein; C H Saely; T Marte; F Schmid; L Koch; P Rein; P Langer; S Aczel; H Drexel
Journal:  Atherosclerosis       Date:  2008-03-04       Impact factor: 5.162

8.  Synergistic effect between lipoprotein lipase and apolipoprotein C3 genes in determining the severity of coronary artery disease.

Authors:  Tarek A Abd-El-Aziz; Randa H Mohamed; Amal S El-Shal
Journal:  J Cardiovasc Transl Res       Date:  2013-02-02       Impact factor: 4.132

9.  Risk scores of common genetic variants for lipid levels influence atherosclerosis and incident coronary heart disease.

Authors:  Aaron Isaacs; Sara M Willems; Daniel Bos; Abbas Dehghan; Albert Hofman; M Arfan Ikram; André G Uitterlinden; Ben A Oostra; Oscar H Franco; Jacqueline C Witteman; Cornelia M van Duijn
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-06-13       Impact factor: 8.311

10.  Associations of polymorphisms in the apolipoprotein APOA1-C3-A5 gene cluster with acute coronary syndrome.

Authors:  Yan Ding; Ming An Zhu; Zhi Xiao Wang; Jing Zhu; Jing Bo Feng; Dong Sheng Li
Journal:  J Biomed Biotechnol       Date:  2012-05-23
View more
  6 in total

Review 1.  Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights.

Authors:  Ricardo Stein; Filipe Ferrari; Fernando Scolari
Journal:  Curr Cardiol Rep       Date:  2019-06-21       Impact factor: 2.931

2.  Erratum: Question Marks Left Over a Quantitative Assessment of Apolipoprotein C3 Gene Polymorphisms.

Authors:  Philipp G Sand
Journal:  Aging Dis       Date:  2016-05-27       Impact factor: 6.745

3.  Association between APOC3 polymorphisms and non-alcoholic fatty liver disease risk: a meta-analysis.

Authors:  Jun Wang; Chuncui Ye; Sujuan Fei
Journal:  Afr Health Sci       Date:  2020-12       Impact factor: 0.927

Review 4.  Apolipoprotein C3 gene variants and the risk of coronary heart disease: A meta-analysis.

Authors:  Yan Li; Chao Li; Jie Gao
Journal:  Meta Gene       Date:  2016-04-23

Review 5.  Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?

Authors:  Marja-Riitta Taskinen; Jan Borén
Journal:  Curr Atheroscler Rep       Date:  2016-10       Impact factor: 5.113

6.  Association of cytochrome P450 2C19 polymorphisms with coronary heart disease risk: A protocol for systematic review and meta analysis.

Authors:  Yongxin Yang; Yaping Zhang; Ming Ren; Yonglan Wang; Zhuoma Cairang; Rongxiang Lin; Haixia Sun; Jianju Liu
Journal:  Medicine (Baltimore)       Date:  2020-12-11       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.